Drug intelligence / Profile preview

GT988

Development stage: Preclinical
Lead developer: Gluetacs Therapeutics
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

GT988 is an orally bioavailable molecular glue degrader targeting NIMA-related kinase 7 (NEK7), currently in preclinical development by Gluetacs Therapeutics for the treatment of inflammatory diseases. NEK7 is an essential component of the NLRP3 inflammasome, acting as a scaffold that facilitates the assembly and activation of the complex in response to various stimuli. By inducing the targeted degradation of NEK7, GT988 inhibits the downstream production of pro-inflammatory cytokines such as IL-1β and IL-18, offering a potential therapeutic strategy for chronic inflammatory conditions.

Targets

NEK7 (NIMA-related kinase 7)

Beyond the preview

Go deeper on GT988.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT988.

Explore the full profile